Thomas Prébet

Author PubWeight™ 9.98^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.	Blood	2012	1.88
2	BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.	Blood	2013	1.16
3	Protein tyrosine kinase 7 has a conserved role in Wnt/β-catenin canonical signalling.	EMBO Rep	2010	1.13
4	PTK7: a cell polarity receptor with multiple facets.	Cell Cycle	2011	0.95
5	Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.	Exp Hematol	2008	0.94
6	Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure.	Br J Haematol	2012	0.93
7	Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone.	Leuk Res	2010	0.83
8	Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.	Haematologica	2006	0.78
9	[Histone methyltransferases: a new class of therapeutic targets in cancer treatment?].	Med Sci (Paris)	2011	0.78
10	Comparison of 60 or 90 mg/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics.	Am J Hematol	2014	0.77
11	A simplified, 96-well-adapted, ATP luminescence-based motility assay.	Biotechniques	2009	0.75